Table 1.
The distributions of demographic and tumor characteristics of rectal cancer patients in five centers and NCT04271657 trial.
| GDPH (n = 54) | SXCH (n = 185) | SYSU6 (n = 300) | SYSUCC (n = 477) | YNCH (n = 171) | Total (n = 1187) | Cohort 2 (n = 100) | |
|---|---|---|---|---|---|---|---|
| Age, years | |||||||
| Mean ± SD | 55.3 ± 9.9 | 53.6 ± 10.6 | 54.1 ± 11.5 | 54.7 ± 11.6 | 56.1 ± 11.4 | 54.6 ± 11.3 | 57.3 ± 12.1 |
| Sex | |||||||
| Male | 39 (72.2) | 110 (59.5) | 212 (70.7) | 314 (65.8) | 115 (67.3) | 790 (66.6) | 76 (76.0) |
| Female | 15 (27.8) | 75 (40.5) | 88 (29.3) | 163 (34.2) | 56 (32.7) | 397 (33.4) | 24 (24.0) |
| CEA levela | |||||||
| Normal | 45 (83.3) | 116 (62.7) | 178 (59.3) | 266 (55.8) | 91 (53.2) | 696 (58.6) | 0 (0.0) |
| Abnormal | 9 (16.7) | 69 (37.3) | 122 (40.7) | 211 (44.2) | 80 (46.8) | 491 (41.4) | 0 (0.0) |
| NA | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 100 (100) |
| Location | |||||||
| Low | 26 (48.1) | 83 (44.9) | 161 (53.7) | 221 (46.3) | 78 (45.6) | 569 (47.9) | 0 (0.0) |
| Middle | 27 (50.0) | 89 (48.1) | 130 (43.3) | 224 (47.0) | 84 (49.1) | 554 (46.7) | 0 (0.0) |
| High | 1 (1.9) | 13 (7.0) | 9 (3.0) | 32 (6.7) | 9 (5.3) | 64 (5.4) | 0 (0.0) |
| NA | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 100 (100) |
| cTNM stage | |||||||
| II | 3 (5.6) | 26 (14.1) | 52 (17.3) | 78 (16.4) | 34 (19.9) | 193 (16.3) | 0 (0.0) |
| III | 51 (94.4) | 159 (85.9) | 248 (82.7) | 399 (83.6) | 137 (80.1) | 994 (83.7) | 100 (100) |
| mrT stage | |||||||
| T1–T2 | 0 (0.0) | 0 (0.0) | 6 (2.0) | 2 (0.4) | 2 (1.2) | 10 (0.8) | 0 (0.0) |
| T3 | 47 (87.0) | 142 (76.8) | 246 (82.0) | 401 (84.1) | 141 (82.5) | 977 (82.3) | 79 (79.0) |
| T4 | 7 (13.0) | 43 (23.2) | 48 (16.0) | 74 (15.5) | 28 (16.4) | 200 (16.8) | 21 (21.0) |
| mrN stage | |||||||
| N0 | 14 (25.9) | 36 (19.5) | 80 (26.7) | 155 (32.5) | 63 (36.8) | 348 (29.3) | 23 (23.0) |
| N1 | 16 (29.6) | 73 (39.5) | 107 (35.7) | 188 (39.4) | 56 (32.7) | 440 (37.1) | 38 (38.0) |
| N2 | 24 (44.4) | 76 (41.1) | 113 (37.7) | 134 (28.1) | 52 (30.4) | 399 (33.6) | 39 (39.0) |
| mrTD status | |||||||
| Negative | 37 (68.5) | 128 (69.2) | 248 (82.7) | 421 (88.3) | 124 (72.5) | 958 (80.7) | 77 (77.0) |
| Positive | 17 (31.5) | 57 (30.8) | 52 (17.3) | 56 (11.7) | 47 (27.5) | 229 (19.3) | 23 (23.0) |
| mrEMVI status | |||||||
| Negative | 25 (46.3) | 121 (65.4) | 218 (72.7) | 417 (87.4) | 115 (67.2) | 896 (75.5) | 74 (74.0) |
| Positive | 29 (53.7) | 64 (34.6) | 82 (27.3) | 60 (12.6) | 56 (32.7) | 291 (24.5) | 26 (26.0) |
| mrCRM status | |||||||
| Clear | 26 (48.1) | 83 (44.9) | 210 (70.0) | 333 (69.8) | 108 (63.2) | 760 (64.0) | 50 (50.0) |
| Involved | 28 (51.9) | 102 (55.1) | 90 (30.0) | 144 (30.2) | 63 (36.8) | 427 (36.0) | 50 (50.0) |
| mrDEC score | |||||||
| 0 | 20 (37.0) | 61 (33.0) | 174 (58.0) | 303 (63.5) | 76 (44.4) | 634 (53.4) | 40 (40.0) |
| 1 | 8 (14.8) | 59 (31.9) | 59 (19.7) | 117 (24.5) | 45 (26.3) | 288 (24.3) | 34 (34.0) |
| 2 | 12 (22.2) | 31 (16.8) | 36 (12.0) | 28 (5.9) | 29 (17.0) | 136 (11.5) | 13 (13.0) |
| 3 | 14 (25.9) | 34 (18.4) | 31 (10.3) | 29 (6.1) | 21 (12.3) | 129 (10.9) | 13 (13.0) |
| TRG | |||||||
| 0 | 0 (0.0) | 31 (16.8) | 86 (28.7) | 112 (23.5) | 43 (25.1) | 272 (22.9) | 23 (23.0) |
| 1 | 1 (1.9) | 55 (29.7) | 98 (32.7) | 124 (26.0) | 40 (23.4) | 318 (26.8) | 32 (32.0) |
| 2 | 1 (1.9) | 55 (29.7) | 106 (35.3) | 239 (50.1) | 50 (29.2) | 451 (38.0) | 33 (33.0) |
| 3 | 0 (0.0) | 42 (22.7) | 10 (3.3) | 2 (0.4) | 38 (22.2) | 92 (7.8) | 12 (12.0) |
| NA | 52 (96.3) | 2 (1.1) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 54 (4.5) | 0 (0.0) |
CEA carcinoembryonic antigen, TNM tumor-node-metastasis, mr magnetic resonance, TD tumor deposit, EMVI extramural vascular invasion, CRM circumferential resection margin, TRG tumor regression grade, NA not applicable.
Unless otherwise indicated, data are number of patients, and data in parentheses are percentages.
aThe normal values for CEA level range from 0 to 5 ng/ml.